• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
CDY
Click for more information
1.43% 7.1¢

CELLMID LIMITED - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
CDY Change of Director's Interest Notices19/11/15
CDY Appendix 3B19/11/15
CDY Results of Meeting12/11/15
CDY AGM Presentation to Shareholders12/11/15
CDY Company Secretary Appointment/Resignation30/10/15
CDY Appendix 4C - quarterlyPRICE SENSITIVE27/10/15
CDY Cellmid 2015 Annual Report to Shareholders12/10/15
CDY Notice of Annual General Meeting/Proxy Form12/10/15
CDY Date of Annual General Meeting28/09/15
CDY Cleansing Statement and Appendix 3B15/09/15
CDY Results of EGM09/09/15
CDY EGM Presentation by CEO09/09/15
CDY Appendix 4G and Corporate Governance Statement31/08/15
CDY Appendix 4E and Preliminary Final ReportPRICE SENSITIVE31/08/15
CDY Cellmid Launching Major Advertising CampaignPRICE SENSITIVE27/08/15
CDY Appendix 3Y - Dr Edward Fintan Walton13/08/15
CDY Cellmid appoints EAS to support US StrategyPRICE SENSITIVE12/08/15
CDY Notice of Extraordinary General Meeting/Proxy Form10/08/15
CDY CDY Newsletter August 201506/08/15
CDY Cleansing Notice and Appendix 3B05/08/15
CDY Appendix 4C - quarterlyPRICE SENSITIVE30/07/15
CDY Cellmid raises $4M to leverage sales growthPRICE SENSITIVE30/07/15
CDY Trading HaltPRICE SENSITIVE28/07/15
CDY Appendix 3X - Dr Edward Fintan Walton23/07/15
CDY Cellmid Appoints Dr Fintan Walton as Director21/07/15
CDY Letter to Shareholders15/07/15
CDY Cellmid Revenue Guidance UpgradePRICE SENSITIVE09/07/15
CDY Dr Bryce Vissel to Chair Cellmid's Scientific Advisory Board07/07/15
CDY Initial Director's Interest Notice - B Gordon01/07/15
CDY Final Director's Interest Notice - M Rogers01/07/15
CDY Final Director's Interest Notice - G Kaufman01/07/15
CDY Details of Share Registry address30/06/15
CDY US Patent for Anti-Midkine Antibodies GrantedPRICE SENSITIVE29/06/15
CDY Cellmid Announces Brain Cancer ProgramPRICE SENSITIVE23/06/15
CDY Cellmid Invited to Present at Breakfast @ BIO17/06/15
CDY Positive Toxicology Study Results for CAB102PRICE SENSITIVE15/06/15
CDY Cellmid Signs Agreement with MaywufaPRICE SENSITIVE02/06/15
CDY Director Appointment / Resignation26/05/15
CDY Appendix 3B19/05/15
CDY Cellmid Secures $1M Loan FundingPRICE SENSITIVE15/05/15
CDY Appendix 4C - quarterlyPRICE SENSITIVE29/04/15
CDY Positive Clinical Results for Cellmid Hair Growth ProductPRICE SENSITIVE15/04/15
CDY Cellmid Presenting at World Congress on Angiogenesis13/04/15
CDY Company Secretary Appointment/Resignation31/03/15
CDY Change of Director's Interest Notice10/03/15
CDY NSW Broker Meets Biotech Presentation04/03/15
CDY Appendix 4D and Half Year AccountsPRICE SENSITIVE24/02/15
CDY February 2015 Newsletter11/02/15
CDY Appendix 4C - quarterlyPRICE SENSITIVE28/01/15
CDY USA Patent Granted for Treatment of Heart FailurePRICE SENSITIVE21/01/15
CDY Australian Patent Granted for Use of Midkine for Hair GrowthPRICE SENSITIVE12/01/15
CDY Cleansing Notice and Appendix 3B18/12/14
CDY Key Midkine Antibody Patent GrantedPRICE SENSITIVE15/12/14
CDY Cellmid Capital RaisingPRICE SENSITIVE15/12/14
CDY Trading HaltPRICE SENSITIVE11/12/14
CDY Cellmid signs agreement with ZoetisPRICE SENSITIVE17/11/14
CDY Appendix 4C - quarterlyPRICE SENSITIVE29/10/14
CDY Results of Annual General Meeting10/10/14
CDY AGM Presentation by CEO10/10/14
CDY Change of Director's Interest Notice19/09/14
CDY Annual Report to shareholders 201416/09/14
CDY Notice of Annual General Meeting and Proxy Form08/09/14
CDY Appendix 4E and Preliminary Final ReportPRICE SENSITIVE29/08/14
CDY Date of Annual General Meeting20/08/14
CDY Cellmid Newsletter18/08/14
CDY Cleansing Notice and Appendix 3B15/08/14
CDY Appendix 4C - quarterlyPRICE SENSITIVE29/07/14
CDY Cellmid Granted UK Patent for Use of Midkine for Hair GrowthPRICE SENSITIVE16/07/14
CDY Landmark Study- FGF5 Critical Regulator of Human Hair GrowthPRICE SENSITIVE15/07/14
CDY Quest Diagnostic License UpdatePRICE SENSITIVE20/06/14
CDY Manufacturing Partner Appointed by CellmidPRICE SENSITIVE19/06/14
CDYChange of Director's Interest Notice - Graeme Kaufman02/06/14
CDYNotice of ceasing to be a substantial holder20/05/14
CDYKey Milestone Completed, Lead Antibody SelectedPRICE SENSITIVE07/05/14
CDYSignificant New Findings Presented at 3rd Midkine SymposiumPRICE SENSITIVE30/04/14
CDYAppendix 4C - quarterlyPRICE SENSITIVE28/04/14
CDYRelease of Shares from Voluntary Escrow22/04/14
CDYCellmid Signs Mk Tribody Collaboration Agreement15/04/14
CDYPresentation to the Market31/03/14
CDYCellmid News24/03/14
CDYAppendix 4D and Half Yearly AccountsPRICE SENSITIVE27/02/14
CDYCleansing Notice and Appendix 3B17/02/14
CDYUSA RNA/DNA Patent for Surgical Adhesion AllowedPRICE SENSITIVE10/02/14
CDYChinese Distribution Agreement Signed for Hair Loss ProductsPRICE SENSITIVE29/01/14
CDYAppendix 4C - quarterlyPRICE SENSITIVE28/01/14
CDYResponse to ASX Query08/01/14
CDYChange of Director's Interest Notice - Maria Halasz06/01/14
CDYCleansing Notice and Appendix 3B20/12/13
CDYResults of Completed CK3000 Diagnostic StudyPRICE SENSITIVE18/12/13
CDYCapital Raising of $2 millionPRICE SENSITIVE11/12/13
CDYTrading HaltPRICE SENSITIVE09/12/13
CDYChange of Director's Interest Notice - Maria Halasz25/11/13
CDYCleansing Statement25/11/13
CDYAppendix 3B and Change of Interests of Substantial Holder25/11/13
CDYResults of Meeting22/11/13
CDYAGM PRESENTATION BY CEO22/11/13
CDYChange in substantial holding20/11/13
CDYProposed Issue of Shares18/11/13
CDYRelease of Shares from Voluntary Escrow30/10/13
CDYCellmid News23/10/13
CDY Change of Director's Interest Notices
19/11/15
CDY Appendix 3B
19/11/15
CDY Results of Meeting
12/11/15
CDY AGM Presentation to Shareholders
12/11/15
CDY Company Secretary Appointment/Resignation
30/10/15
CDY Appendix 4C - quarterly
27/10/15PRICE SENSITIVE
CDY Cellmid 2015 Annual Report to Shareholders
12/10/15
CDY Notice of Annual General Meeting/Proxy Form
12/10/15
CDY Date of Annual General Meeting
28/09/15
CDY Cleansing Statement and Appendix 3B
15/09/15
CDY Results of EGM
09/09/15
CDY EGM Presentation by CEO
09/09/15
CDY Appendix 4G and Corporate Governance Statement
31/08/15
CDY Appendix 4E and Preliminary Final Report
31/08/15PRICE SENSITIVE
CDY Cellmid Launching Major Advertising Campaign
27/08/15PRICE SENSITIVE
CDY Appendix 3Y - Dr Edward Fintan Walton
13/08/15
CDY Cellmid appoints EAS to support US Strategy
12/08/15PRICE SENSITIVE
CDY Notice of Extraordinary General Meeting/Proxy Form
10/08/15
CDY CDY Newsletter August 2015
06/08/15
CDY Cleansing Notice and Appendix 3B
05/08/15
CDY Appendix 4C - quarterly
30/07/15PRICE SENSITIVE
CDY Cellmid raises $4M to leverage sales growth
30/07/15PRICE SENSITIVE
CDY Trading Halt
28/07/15PRICE SENSITIVE
CDY Appendix 3X - Dr Edward Fintan Walton
23/07/15
CDY Cellmid Appoints Dr Fintan Walton as Director
21/07/15
CDY Letter to Shareholders
15/07/15
CDY Cellmid Revenue Guidance Upgrade
09/07/15PRICE SENSITIVE
CDY Dr Bryce Vissel to Chair Cellmid's Scientific Advisory Board
07/07/15
CDY Initial Director's Interest Notice - B Gordon
01/07/15
CDY Final Director's Interest Notice - M Rogers
01/07/15
CDY Final Director's Interest Notice - G Kaufman
01/07/15
CDY Details of Share Registry address
30/06/15
CDY US Patent for Anti-Midkine Antibodies Granted
29/06/15PRICE SENSITIVE
CDY Cellmid Announces Brain Cancer Program
23/06/15PRICE SENSITIVE
CDY Cellmid Invited to Present at Breakfast @ BIO
17/06/15
CDY Positive Toxicology Study Results for CAB102
15/06/15PRICE SENSITIVE
CDY Cellmid Signs Agreement with Maywufa
02/06/15PRICE SENSITIVE
CDY Director Appointment / Resignation
26/05/15
CDY Appendix 3B
19/05/15
CDY Cellmid Secures $1M Loan Funding
15/05/15PRICE SENSITIVE
CDY Appendix 4C - quarterly
29/04/15PRICE SENSITIVE
CDY Positive Clinical Results for Cellmid Hair Growth Product
15/04/15PRICE SENSITIVE
CDY Cellmid Presenting at World Congress on Angiogenesis
13/04/15
CDY Company Secretary Appointment/Resignation
31/03/15
CDY Change of Director's Interest Notice
10/03/15
CDY NSW Broker Meets Biotech Presentation
04/03/15
CDY Appendix 4D and Half Year Accounts
24/02/15PRICE SENSITIVE
CDY February 2015 Newsletter
11/02/15
CDY Appendix 4C - quarterly
28/01/15PRICE SENSITIVE
CDY USA Patent Granted for Treatment of Heart Failure
21/01/15PRICE SENSITIVE
CDY Australian Patent Granted for Use of Midkine for Hair Growth
12/01/15PRICE SENSITIVE
CDY Cleansing Notice and Appendix 3B
18/12/14
CDY Key Midkine Antibody Patent Granted
15/12/14PRICE SENSITIVE
CDY Cellmid Capital Raising
15/12/14PRICE SENSITIVE
CDY Trading Halt
11/12/14PRICE SENSITIVE
CDY Cellmid signs agreement with Zoetis
17/11/14PRICE SENSITIVE
CDY Appendix 4C - quarterly
29/10/14PRICE SENSITIVE
CDY Results of Annual General Meeting
10/10/14
CDY AGM Presentation by CEO
10/10/14
CDY Change of Director's Interest Notice
19/09/14
CDY Annual Report to shareholders 2014
16/09/14
CDY Notice of Annual General Meeting and Proxy Form
08/09/14
CDY Appendix 4E and Preliminary Final Report
29/08/14PRICE SENSITIVE
CDY Date of Annual General Meeting
20/08/14
CDY Cellmid Newsletter
18/08/14
CDY Cleansing Notice and Appendix 3B
15/08/14
CDY Appendix 4C - quarterly
29/07/14PRICE SENSITIVE
CDY Cellmid Granted UK Patent for Use of Midkine for Hair Growth
16/07/14PRICE SENSITIVE
CDY Landmark Study- FGF5 Critical Regulator of Human Hair Growth
15/07/14PRICE SENSITIVE
CDY Quest Diagnostic License Update
20/06/14PRICE SENSITIVE
CDY Manufacturing Partner Appointed by Cellmid
19/06/14PRICE SENSITIVE
CDYChange of Director's Interest Notice - Graeme Kaufman
02/06/14
CDYNotice of ceasing to be a substantial holder
20/05/14
CDYKey Milestone Completed, Lead Antibody Selected
07/05/14PRICE SENSITIVE
CDYSignificant New Findings Presented at 3rd Midkine Symposium
30/04/14PRICE SENSITIVE
CDYAppendix 4C - quarterly
28/04/14PRICE SENSITIVE
CDYRelease of Shares from Voluntary Escrow
22/04/14
CDYCellmid Signs Mk Tribody Collaboration Agreement
15/04/14
CDYPresentation to the Market
31/03/14
CDYCellmid News
24/03/14
CDYAppendix 4D and Half Yearly Accounts
27/02/14PRICE SENSITIVE
CDYCleansing Notice and Appendix 3B
17/02/14
CDYUSA RNA/DNA Patent for Surgical Adhesion Allowed
10/02/14PRICE SENSITIVE
CDYChinese Distribution Agreement Signed for Hair Loss Products
29/01/14PRICE SENSITIVE
CDYAppendix 4C - quarterly
28/01/14PRICE SENSITIVE
CDYResponse to ASX Query
08/01/14
CDYChange of Director's Interest Notice - Maria Halasz
06/01/14
CDYCleansing Notice and Appendix 3B
20/12/13
CDYResults of Completed CK3000 Diagnostic Study
18/12/13PRICE SENSITIVE
CDYCapital Raising of $2 million
11/12/13PRICE SENSITIVE
CDYTrading Halt
09/12/13PRICE SENSITIVE
CDYChange of Director's Interest Notice - Maria Halasz
25/11/13
CDYCleansing Statement
25/11/13
CDYAppendix 3B and Change of Interests of Substantial Holder
25/11/13
CDYResults of Meeting
22/11/13
CDYAGM PRESENTATION BY CEO
22/11/13
CDYChange in substantial holding
20/11/13
CDYProposed Issue of Shares
18/11/13
CDYRelease of Shares from Voluntary Escrow
30/10/13
CDYCellmid News
23/10/13
refresh Created with Sketch. REFRESH
 

Top Stories

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

Samples among the highest-ever-graded uranium soil samples recorded in mineral exploration history, and an imminent drill run.
This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 
HotCopper Highlights: Your most watched stocks for Week 48, 2024 Good afternoon, a happy end of the week, and welcome to HotCopper Highlights – I’m Jonathon Davidson. Let’s get into it.
Breaking news: New opportunities for investors & companies - HotCopper opens to capital raising! Companies can now raise capital through HotCopper! It’s a development allowing a highly cost-effective service to ASX-listed companies, while opening new investment opportunities to investors.
Week 48 Wrap: ASX flirts with 8,500pts; APRA declines mortgage loan easing; Trump's Bessent tied to Dem donor The ASX200 has been really flirting with the 8,500pts mark this week, notching an intraweek ATH of 8,476pts.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.